{"id":257,"date":"2024-11-12T16:04:36","date_gmt":"2024-11-12T16:04:36","guid":{"rendered":"https:\/\/clinicaltrials.eg427.com\/?page_id=257"},"modified":"2024-11-19T21:14:28","modified_gmt":"2024-11-19T21:14:28","slug":"legal-notices-and-privacy-policy","status":"publish","type":"page","link":"https:\/\/clinicaltrials.eg427.com\/es\/legal-notices-and-privacy-policy\/","title":{"rendered":"Legal Notices and Privacy Policy"},"content":{"rendered":"
\n

INFORMATION:<\/h2>\n

This site is owned by EG427. EG427, concerned about the rights of individuals, especially regarding automated processing, and in a spirit of transparency with its clients, has implemented a policy outlining these processes, the purposes pursued by them, and the means available to individuals to exercise their rights effectively. For further information on personal data protection, please visit the CNIL website.
\nContinuing to browse this site implies unreserved acceptance of the following provisions and terms of use. You accept the use of cookies and other trackers. If you refuse, please click the “home” or “home page” button in your browser. The current online version of these terms is the only enforceable one for the duration of your site use, until a new version replaces it.<\/p>\n

ARTICLE 1: LEGAL INFORMATION<\/h2>\n

1.1 Site (hereafter referred to as \u201cthe site\u201d):<\/h3>\n

EG427<\/p>\n

1.2 Publisher (hereafter referred to as \u201cthe publisher\u201d)<\/h3>\n

Publication Director: Philippe Chambon
\n29 Rue du Faubourg Saint-Jacques,
\n75014 PARIS
\nCapital: \u20ac 16,058.30
\nSiret: 85122559900022
\nVAT: FR04851225599<\/p>\n

Contact via messaging or through the contact form accessible on this site in the “CONTACT” section of the top menu of this page.<\/p>\n

1.3 Hosting:<\/h3>\n

\u2022Agency Orocom \/ Dovel<\/p>\n

\u2022More information at orocom.fr<\/a><\/p>\n

1.4 Host & Service Provider:<\/h3>\n

\u2013 1.4.1 Site Launch & Maintenance:<\/strong>
\n\u2022 Launch and follow-up of the site with the agreement of EG427,
\n\u2022 Orocom continuously monitors the site but disclaims any responsibility for technical issues from the host or client, the usage, modification, and nature of the content, or any site modifications by the client.<\/p>\n

\u2013 1.4.2 Hosting & Domain Name:<\/strong>
\n\u2022 Domain by: Orocom c\/o OVH.com, 2 rue Kellerman, BP 80157, 59100 ROUBAIX
\nServers: Orocom c\/o Titan Datacenters France, SIRET: 78968319000027, 45 ALL DES ORMES 06250 MOUGINS
\nServers: OrocomBaie c\/o Infomaniak Datacenters, Rue Eug\u00e8ne-Marziano 25, 1227 Les Acacias, Switzerland, Trade Registry: CHE-103.167.648<\/p>\n

1.5 This site\u2019s content is available on the following domains:<\/h3>\n

clinicaltrials.eg427.com<\/p>\n

ARTICLE 2: SITE ACCESS<\/h2>\n

Access to and use of the site are strictly for professional use. You agree not to use this site, or the information or data provided, for commercial, political, advertising purposes, or for any commercial solicitation, including unsolicited email.<\/p>\n

ARTICLE 3: SITE CONTENT<\/h2>\n

All trademarks, photos, texts, comments, illustrations, animated or not, video sequences, sounds, and all software applications used to operate this site are generally protected by intellectual property laws. They are the full property of the creator, publisher, or their partners, depending on the agreements established. Any reproduction, representation, use, or adaptation of any part of these elements, including software applications, without the prior written consent of the publisher, is strictly prohibited. Non-action by the publisher upon unauthorized use does not imply acceptance or waiver of legal recourse.
\nIt is also prohibited to copy, modify, create derivative works, reverse engineer, sell, assign, sublicense, or transfer any rights associated with the site. The drafting of this document, called “Legal Notices,” is copyright protected by Dovel. Unauthorized copying or use on another site or for copyright purposes requires prior written consent through our contact form, if available on our website, or by mail.<\/p>\n

ARTICLE 4: SITE MANAGEMENT<\/h2>\n

To manage the site effectively, the publisher may at any time:
\n\u2022 Suspend, interrupt, or restrict access to all or part of the site, reserving access to specific user groups;
\n\u2022 Remove any information that might disrupt the site’s functioning or violate national or international laws, or Netiquette rules;
\n\u2022 Suspend the site to perform updates.<\/p>\n

ARTICLE 5: RESPONSIBILITIES<\/h2>\n

The publisher is not responsible for any hosting provider failures, outages, technical issues, or operational interruptions that prevent access to the site or its features.
\nYour connection equipment is your responsibility. You must take all appropriate measures to protect your equipment and data, especially against internet viruses. You are solely responsible for the software, sites, and data you use and view.<\/p>\n

Neither the publisher nor the provider can be held liable for any legal proceedings brought against you:
\n\u2022 Due to your use of the site or any accessible services via the internet;
\n\u2022 Due to your non-compliance with these terms and conditions.<\/p>\n

The publisher is not liable for damages to you, third parties, and\/or your equipment due to your connection to or use of the site. You hereby waive any claims against the publisher.<\/p>\n

Should the publisher face a legal or amicable procedure due to your use of the site, it may seek compensation from you for any material and non-material damages, judgments, and costs arising from such a procedure.<\/p>\n

ARTICLE 6: HYPERLINKS<\/h2>\n

Creating hyperlinks to any part of this site is, in principle, allowed by the publisher. Any hyperlink must be removed upon the publisher\u2019s request. The publisher does not have control over the content accessed via external links.<\/p>\n

ARTICLE 7: DATA COLLECTION AND PROTECTION<\/h2>\n

Your data is collected by the company named after the site: clinicaltrials.eg427.com. Personal data refers to any information relating to an identified or identifiable individual, directly or indirectly, by reference to a name, identification number, or one or more elements specific to their physical, physiological, genetic, mental, economic, cultural, or social identity.
\nData collected from the site is primarily used by the publisher for customer relationship management, order processing, and responding to your inquiries.<\/p>\n

ARTICLE 8: RIGHT OF ACCESS, RECTIFICATION, AND DEREFERENCING OF YOUR DATA<\/h2>\n

Under the applicable regulations on personal data, users of the site have the following rights:
\n\u2022 Right of access: Users can exercise their right to access their personal data by writing to the email address provided on the website. In this case, before implementing this right, the platform may request proof of the user’s or requester\u2019s identity to verify accuracy.
\n\u2022 Right to rectification: If the personal data held by the platform is inaccurate, users can request the information be updated.
\n\u2022 Right to deletion of data: Users can request the deletion of personal data, in compliance with applicable data protection laws.
\n\u2022 Right to limit processing: Users can request the platform to limit processing of their personal data, as provided for in the GDPR.
\n\u2022 Right to object to data processing: Users may object to data processing, under the conditions stipulated by the GDPR.
\n\u2022 Revoke all cookies: “At the bottom right of your screen, a cookie management window will appear. Click on ‘functional cookies only’ to disable.”
\n\u2022 Right to data portability: Users can ask the platform to provide the personal data they previously submitted for transfer to another platform.<\/p>\n

You can exercise these rights by contacting us via email, the contact form on this site, or by mail. Each request should be accompanied by a photocopy of a valid, signed identity document and specify the contact address for a response. A response is typically issued within one (1) month of receiving the request. This period may be extended by up to two (2) months if the request\u2019s complexity and\/or the volume of requests require.
\nLaw No. 2016-1321 of October 7, 2016, allows individuals to arrange the fate of their data after their death. For more information, visit the CNIL website.
\nUsers may also submit a complaint to the CNIL on their website. Before initiating a complaint, we strongly suggest contacting us for a preliminary and amicable resolution. We will do our best to respond positively to your request.<\/p>\n

ARTICLE 9: DATA USE<\/h2>\n

Personal data collected from users is intended to provide platform services, improve them, and maintain a secure environment. The legal basis for data processing includes the execution of the contract between the user and the platform. Specifically, data is used for:
\n\u2022 Access and use of the platform by the user;
\n\u2022 Management and optimization of platform functionality;
\n\u2022 User support;
\n\u2022 Verification, identification, and authentication of data transmitted by users;
\n\u2022 Customization of services by displaying advertisements based on user preferences;
\n\u2022 Prevention and detection of fraud, malware, and security incidents;
\n\u2022 Handling disputes with users;
\n\u2022 Sending commercial and advertising information based on user preferences;
\n\u2022 Organizing terms for payment services if an e-commerce site is involved.<\/p>\n

ARTICLE 10: DATA RETENTION POLICY<\/h2>\n

The platform retains your data for the time needed to provide its services or assistance, or generally, for a reasonable period necessary to comply with legal and regulatory obligations, resolve disputes, prevent fraud and abuse, and enforce our terms and conditions. Some of your information may also be retained as necessary, even after you have closed your account or we no longer need it to provide services.<\/p>\n

ARTICLE 11: SHARING PERSONAL DATA WITH THIRD PARTIES<\/h2>\n

Personal data may be shared with third parties within the European Union in the following cases:
\n\u2022 When the user utilizes payment services, the platform partners with third-party financial institutions to implement these services;
\n\u2022 When users publish information in open comment areas;
\n\u2022 When users authorize a third-party website to access their data;
\n\u2022 When the platform hires service providers for user support, advertising, and payment services. Providers have limited access to the user\u2019s data under contract and are bound to use it per personal data protection regulations;
\n\u2022 If required by law, the platform may transmit data to comply with claims against the platform according to administrative and legal procedures.<\/p>\n

ARTICLE 12.1: CMS: Comments<\/h2>\n

When you leave a comment on our website, the data entered in the comment form, as well as your IP address and browser\u2019s user agent, are collected to help detect unwanted comments.
\nAn anonymized string created from your email address (also called a hash) may be sent to the Gravatar service to verify if you use it. Gravatar’s privacy policy is available here: https:\/\/automattic.com\/privacy\/. After approval, your profile picture is publicly visible next to your comment.
\nData storage periods
\n\u2022 If you leave a comment, the comment and its metadata are retained indefinitely, allowing us to recognize and approve any follow-up comments automatically rather than holding them in a moderation queue.
\n\u2022 If you have an account or have left comments on the site, you can request a file containing all the personal data we have about you, including any you have provided. You can also request that your personal data be deleted. This does not include data kept for administrative, legal, or security purposes.
\n\u2022 Visitor comments may be checked through an automated spam detection service.<\/p>\n

ARTICLE 12.2: CMS: Media<\/h2>\n

If you upload images to the website as a registered user, avoid uploading images containing GPS EXIF data. Visitors to the website can download and extract location data from these images.<\/p>\n

ARTICLE 12.3: CMS: Embedded Content from Other Sites<\/h2>\n

Articles on this site may include embedded content (e.g., videos, images, articles). Embedded content behaves as if the visitor visited the other site directly. These websites could collect data, use cookies, embed third-party tracking tools, and monitor interactions with the embedded content if you have an account connected to their website.<\/p>\n

ARTICLE 13: COMMERCIAL OFFERS<\/h2>\n

You may receive commercial offers from the publisher. If you do not wish to receive these offers, close your browser or conduct a new search to leave the current site.
\nYour data is not transferred to any partners or third parties. It is exclusively for the publisher\u2019s internal use, to respond to your inquiries or provide relevant information. However, if you prefer not to receive this, please leave the site.
\nIf you access personal data while browsing, you must refrain from any unauthorized collection, usage, or actions that may infringe on individuals’ privacy or reputation. The publisher disclaims any liability in this regard.
\nData is stored and used for a duration in compliance with current legislation.<\/p>\n

ARTICLE 14: COOKIES<\/h2>\n

What is a \u201ccookie\u201d?
\nA cookie is a file (or tracker or electronic tag) stored by the browser on an electronic device such as your computer, tablet, or smartphone when browsing the internet. It is a text file generated by the server of the website you visit or a third-party application server (ad network, internet traffic analysis software, messaging, etc.).
\nFor more information, visit the CNIL website.<\/p>\n

By browsing this site, \u201ccookies\u201d from the responsible site or third parties may be placed on your device, regardless of their type. During your first visit, a banner explaining cookie use will appear. By continuing, you are considered informed and have accepted the use of these \u201ccookies.\u201d Consent is valid for up to thirteen (13) months. You can disable cookies in your browser settings. Cookies used on this site include:<\/p>\n

CMS:<\/h3>\n

When you comment, cookies store information like your name, email, and website for your convenience, so you don\u2019t need to re-enter it when leaving another comment. These cookies expire after one year.
\nAdditional cookies for session management, security, SEO, XML Sitemaps, page-specific SEO, SEO keywords, meta necessary for SEO, and IP address for auto-protection purposes.
\nCookie lifespan is up to thirteen (13) months. Visit the CNIL website for more on managing cookies.<\/p>\n

ARTICLE 15: PHOTOS, VIDEOS & PRODUCT REPRESENTATION<\/h2>\n

Unless otherwise stated, all photographs, videos of products, equipment, and locations, with or without descriptions, fully belong to the website manager.
\nAlthough non-contractual and not necessarily binding on the publisher, any partial or complete reproduction, modification, or use must be requested in writing through our contact form.
\nUnauthorized online publication, even on a public site, constitutes a copyright infringement.<\/p>\n

ARTICLE 16: APPLICABLE LAW<\/h2>\n

These site terms of use are governed by French law and fall under the jurisdiction of the courts at the publisher\u2019s registered office, subject to specific jurisdiction arising from particular laws or regulations.<\/p>\n

ARTICLE 17: CONTACT US<\/h2>\n

For any questions or information regarding a product, location, or service featured on the site or about the site itself, you can send us a message via the contact form, where you will find our complete contact information.<\/p>\n

ARTICLE 18: LEGAL NOTICES<\/h2>\n

Copying or imitating these legal notices is strictly prohibited.<\/p>\n

\u2022<\/span><\/p>\n

\u2022<\/span><\/p>\n

\u2022<\/span><\/p>\n

Website Privacy Notice<\/span><\/h2>\n

\u2022<\/span><\/p>\n

1.\u00a0 Privacy Specifics<\/h1>\n

<\/a>Privacy Notice to US Users<\/h2>\n

For the processing of Personal Information related to the use of this website, EG427 is committed to comply with the applicable Federal and State Laws, including:<\/p>\n

\u2022California Consumer Privacy Act 2018 (hereinafter the “CCPA”), The California Consumer Privacy Rights Act 2020 (hereinafter “CPRA”), The Californian Online Privacy Protection Act 2003 (hereinafter the “CalOPPA”);<\/p>\n

\u2022Colorado Privacy Act (\u201cCPA\u201d);<\/p>\n

\u2022Connecticut Data Privacy Act (\u201cCDPA\u201d);<\/p>\n

\u2022Oregon Consumer Privacy Act (\u201cOCPA\u201d);<\/p>\n

\u2022Texas Data Privacy and Security Act (\u201cTDPSA\u201d);<\/p>\n

\u2022Utah Consumer Privacy Act (\u201cUCPA\u201d);<\/p>\n

\u2022Virginia Consumer Data Protection Act (\u201cVCPA\u201d).<\/p>\n

Collectively referred as \u201cPrivacy Laws\u201d.<\/p>\n

Depending on the State where you reside, your rights and the information that must be provided to you may vary. We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers. If you are a underage 18 and a registered user of the Services, you may ask us to remove content or data that you have posted to the Services by emailing: \u00a0EG427.dpo@mydata-trust.info<\/a>. Please note that your request does not ensure complete or comprehensive removal of the content or data, if, for example, EG427 is required by law to maintain the data.<\/p>\n

<\/a>\u00a0<\/strong><\/p>\n

Transfer of personal data<\/h3>\n

\u00a0<\/strong><\/p>\n

Processing of information will take place in France and USA. If you reside outside France, your information will be transferred to France securely, where it will be processed and stored under European and French privacy standards.<\/p>\n

\u00a0<\/strong><\/p>\n

Your Privacy Rights<\/h3>\n

\u00a0<\/strong><\/p>\n

<\/a>Do Not Track (“DNT”) requests<\/em><\/strong>.<\/p>\n

Some web browsers incorporate a “do-not-track” that signals to websites with which the browser communicates that a visitor does not want to have his\/her online activity tracked. As of the October 2023, not all browsers offer a DNT option and DNT signals are not yet uniform. For this reason, EG427 along with many other digital service operators do not currently respond to DNT signals. Therefore, if you don\u2019t want to be tracked, please select the refuse Button available on the Cookies Banner or select your preference under the cookie settings. For more information about DNT signals, visit allaboutdnt.com.<\/p>\n

If you are a California, Colorado, Connecticut, Oregon, Texas, Utah, or Virginia<\/u><\/strong> resident, you have the rights listed below. Notice that these rights are not absolute, and we may decline to honor your request where an exception applies, such as where the disclosure of Personal Information would adversely affect the rights and freedoms of another resident.<\/p>\n

Information<\/strong>. Disclose to you the following information:<\/p>\n

\u2022The categories of Personal Information we collected about you and the categories of sources from which we collected such Personal Information.<\/p>\n

\u2022The specific pieces of Personal Information we collected about you.<\/p>\n

\u2022The business or commercial purpose for collecting Personal Information about you; and<\/p>\n

\u2022The categories of Personal Information about you that we otherwise shared or disclosed and the categories of third parties with whom we shared or to whom we disclosed such Personal Information.<\/p>\n

Access<\/strong>. Request a copy of the Personal Information that we maintain about you.<\/p>\n

Deletion<\/strong>. Delete Personal Information we collected from you.<\/p>\n

Nondiscrimination<\/strong>. You are entitled to exercise the rights described above free from discrimination. This means that we will not penalize you for exercising your rights by taking actions such as:<\/p>\n

\u2022Denying you goods or services<\/p>\n

\u2022Increasing the price\/rate of goods or services<\/p>\n

\u2022Decreasing the service quality<\/p>\n

\u2022Suggesting that we may penalize you as described above for exercising your rights<\/p>\n

Depending on the State where you reside you may have additional rights.<\/p>\n

<\/a>California:<\/u><\/em><\/strong><\/p>\n

Rectification<\/strong>: You may ask us to correct inaccurate Personal Information we maintain about you.<\/p>\n

“Shine the Light “and “Eraser” Laws.<\/strong>\u00a0 You may request a list of all third parties to which we have disclosed certain information for those third parties\u2019 direct marketing purposes.<\/p>\n

Opt out of sale or sharing<\/strong>. You can ask us not to sell or share your Personal Information.\u00a0 If we know that you are younger than 16 years old, we will ask for your permission (or if you are under 13 years old, your parent or guardian\u2019s permission) to sell or share your Personal Information before we do so.<\/p>\n

Limit use of sensitive personal information.<\/strong> You have the right to direct us to limit the use of your sensitive personal information to what\u2019s necessary or reasonably expected to perform the service or provide the goods.<\/p>\n

<\/a>\u00a0<\/em><\/strong><\/p>\n

Colorado, Connecticut, Oregon, Texas and Virginia:<\/u><\/em><\/strong><\/p>\n

Rectification<\/strong>: correct inaccurate Personal Information we maintain about you.<\/p>\n

Opt-out of targeted advertising, sale or profiling. <\/strong>You can ask us to not process your Personal Information for targeting advertising, not to sale your Personal Information or not to process your Personal Information in a way that may constitute profiling in furtherance of decisions that produce legal or similarly significant effects for you.<\/p>\n

<\/a>\u00a0<\/em><\/strong><\/p>\n

Utah:<\/u><\/em><\/strong><\/p>\n

Opt-out of targeted advertising or sale of Personal Information<\/strong>. You can ask us to not process your Personal Information for targeting advertising or not to sale your Personal Information.<\/p>\n

<\/a>\u00a0<\/strong><\/p>\n

How to exercise your rights?<\/h3>\n

\u00a0<\/strong><\/p>\n

You may exercise your rights by contacting us at\u00a0EG427.dpo@mydata-trust.info<\/a> or by completing our online form on our website, by clicking here<\/a>. You can exercise your opt-out rights through the Cookies Banner. To modify your Cookies selection, click on \u00ab Manage consent \u00bb on the bottom right-hand corner of the page.<\/span><\/p>\n

If you are a resident in Colorado, Connecticut, Oregon, Texas or Virginia<\/u><\/strong>, you have the right to appeal our decision regarding your request to exercise your rights through at\u00a0EG427.dpo@mydata-trust.info<\/a> or by completing our online form on our website, by clicking here<\/a>.<\/p>\n

You also have the right to lodge a complaint if you consider that your Personal Information has not been processed in accordance with the Privacy Laws applicable in your State of residence:<\/p>\n

California<\/em><\/strong>:
\nCalifornia Privacy Protection Agency: info@cppa.ca.gov<\/a>
\n<\/u>Attorney General Website: https:\/\/oag.ca.gov\/contact<\/a><\/p>\n

Colorado<\/em><\/strong>:
\nAttorney General website: https:\/\/complaints.coag.gov\/s\/contact-us<\/a><\/p>\n

Connecticut<\/em><\/strong>:
\nAttorney General website:\u00a0 https:\/\/portal.ct.gov\/AG\/Contact-the-Attorney-Generals-Office\/Contact-the-Attorney-Generals-Office#:~:text=For%20all%20general%20inquiries%2C%20please,call%20860%2D808%2D5318<\/a>.<\/p>\n

Oregon<\/em><\/strong>:
\nAttorney General website: https:\/\/www.doj.state.or.us\/consumer-protection\/contact-us\/<\/a><\/p>\n

Texas<\/em><\/strong>:
\nAttorney General website:\u00a0 https:\/\/www.texasattorneygeneral.gov\/contact-us<\/a><\/p>\n

Virginia<\/em><\/strong>:
\nAttorney General website: https:\/\/www.oag.state.va.us\/consumer-protection\/index.php\/file-a-complaint<\/a><\/p>\n

Utah<\/em><\/strong>:
\nAttorney General website:\u00a0\u00a0\u00a0\u00a0\u00a0 https:\/\/www.attorneygeneral.utah.gov\/contact\/complaint-form\/<\/a><\/p>\n

We do not sell personal information<\/h3>\n

We do not \u201csold\u201d Personal Information. For purposes of this specific Privacy Notice, \u201csold\u201d or \u201csale\u201d means the disclosure of Personal Information for monetary or other valuable consideration but does not include, for example, the transfer of Personal Information as an asset that is part of a merger, bankruptcy, or other disposition of all or any portion of our business.<\/p>\n

Drafted by \u00a9orocom.fr<\/em><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

INFORMATION: This site is owned by EG427. EG427, concerned about the rights of individuals, especially regarding automated processing, and in a spirit of transparency with its clients, has implemented a policy outlining these processes, the purposes pursued by them, and the means available to individuals to exercise their rights effectively. For further information on personal […]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-257","page","type-page","status-publish","hentry"],"yoast_head":"\nLegal Notices and Privacy Policy - Clinical trials | EG 427<\/title>\n<meta name=\"description\" content=\"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinicaltrials.eg427.com\/es\/legal-notices-and-privacy-policy\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Legal Notices and Privacy Policy - Clinical trials | EG 427\" \/>\n<meta property=\"og:description\" content=\"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinicaltrials.eg427.com\/es\/legal-notices-and-privacy-policy\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical trials | EG 427\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-19T21:14:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Map_updated.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1040\" \/>\n\t<meta property=\"og:image:height\" content=\"863\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/legal-notices-and-privacy-policy\\\/\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/legal-notices-and-privacy-policy\\\/\",\"name\":\"Legal Notices and Privacy Policy - Clinical trials | EG 427\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#website\"},\"datePublished\":\"2024-11-12T16:04:36+00:00\",\"dateModified\":\"2024-11-19T21:14:28+00:00\",\"description\":\"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/legal-notices-and-privacy-policy\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clinicaltrials.eg427.com\\\/legal-notices-and-privacy-policy\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/legal-notices-and-privacy-policy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Legal Notices and Privacy Policy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#website\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\",\"name\":\"Clinical trials | EG 427\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#organization\"},\"alternateName\":\"Clinical trials | EG 427\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#organization\",\"name\":\"Clinical trials | EG 427\",\"alternateName\":\"Clinical trials\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Design-6.png\",\"contentUrl\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Design-6.png\",\"width\":804,\"height\":1156,\"caption\":\"Clinical trials | EG 427\"},\"image\":{\"@id\":\"https:\\\/\\\/clinicaltrials.eg427.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Legal Notices and Privacy Policy - Clinical trials | EG 427","description":"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinicaltrials.eg427.com\/es\/legal-notices-and-privacy-policy\/","og_locale":"es_ES","og_type":"article","og_title":"Legal Notices and Privacy Policy - Clinical trials | EG 427","og_description":"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.","og_url":"https:\/\/clinicaltrials.eg427.com\/es\/legal-notices-and-privacy-policy\/","og_site_name":"Clinical trials | EG 427","article_modified_time":"2024-11-19T21:14:28+00:00","og_image":[{"width":1040,"height":863,"url":"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Map_updated.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"17 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clinicaltrials.eg427.com\/legal-notices-and-privacy-policy\/","url":"https:\/\/clinicaltrials.eg427.com\/legal-notices-and-privacy-policy\/","name":"Legal Notices and Privacy Policy - Clinical trials | EG 427","isPartOf":{"@id":"https:\/\/clinicaltrials.eg427.com\/#website"},"datePublished":"2024-11-12T16:04:36+00:00","dateModified":"2024-11-19T21:14:28+00:00","description":"Explore EG 427's clinical study EG110A-001-01, aimed at treating neurogenic detrusor overactivity in patients with spinal cord injuries.","breadcrumb":{"@id":"https:\/\/clinicaltrials.eg427.com\/legal-notices-and-privacy-policy\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinicaltrials.eg427.com\/legal-notices-and-privacy-policy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clinicaltrials.eg427.com\/legal-notices-and-privacy-policy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/clinicaltrials.eg427.com\/"},{"@type":"ListItem","position":2,"name":"Legal Notices and Privacy Policy"}]},{"@type":"WebSite","@id":"https:\/\/clinicaltrials.eg427.com\/#website","url":"https:\/\/clinicaltrials.eg427.com\/","name":"Clinical trials | EG 427","description":"","publisher":{"@id":"https:\/\/clinicaltrials.eg427.com\/#organization"},"alternateName":"Clinical trials | EG 427","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinicaltrials.eg427.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/clinicaltrials.eg427.com\/#organization","name":"Clinical trials | EG 427","alternateName":"Clinical trials","url":"https:\/\/clinicaltrials.eg427.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/clinicaltrials.eg427.com\/#\/schema\/logo\/image\/","url":"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Design-6.png","contentUrl":"https:\/\/clinicaltrials.eg427.com\/wp-content\/uploads\/2024\/10\/Design-6.png","width":804,"height":1156,"caption":"Clinical trials | EG 427"},"image":{"@id":"https:\/\/clinicaltrials.eg427.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages\/257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/comments?post=257"}],"version-history":[{"count":19,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages\/257\/revisions"}],"predecessor-version":[{"id":307,"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/pages\/257\/revisions\/307"}],"wp:attachment":[{"href":"https:\/\/clinicaltrials.eg427.com\/es\/wp-json\/wp\/v2\/media?parent=257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}